MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
63.75
+0.24 (+0.38%)
At close: 4:00PM EDT

63.75 0.00 (0.00%)
After hours: 5:28PM EDT

Stock chart is not supported by your current browser
Previous Close63.51
Open63.64
Bid63.78 x 100
Ask64.26 x 400
Day's Range63.59 - 64.03
52 Week Range58.29 - 66.80
Volume9,229,656
Avg. Volume7,737,409
Market Cap173.87B
Beta0.94
PE Ratio (TTM)34.52
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.88 (2.85%)
Ex-Dividend Date2017-09-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • There's no reason for investors to sell stocks now: NYSE trader
    Yahoo Finance Video4 hours ago

    There's no reason for investors to sell stocks now: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss current headwinds for US equities, including the nomination of a new (or same) Federal Reserve Chair in a few weeks.

  • Reuters4 hours ago

    Merck cyber attack may cost insurers $275 mln - Verisk's PCS

    Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit. Merck, however, has not disclosed the magnitude of its uninsured losses from the "NotPetya" attack, which disrupted production of some Merck medicines and vaccines. "Merck has not yet fully quantified its losses, much less given any of its insurers an estimate of the total amount of those losses," Merck spokeswoman Claire Gillespie said in a statement.

  • Merck cyber attack may cost insurers $275 million: Verisk's PCS
    Reuters4 hours ago

    Merck cyber attack may cost insurers $275 million: Verisk's PCS

    Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit. Merck, however, has not disclosed the magnitude of its uninsured losses from the "NotPetya" attack, which disrupted production of some Merck medicines and vaccines. "Merck has not yet fully quantified its losses, much less given any of its insurers an estimate of the total amount of those losses," Merck spokeswoman Claire Gillespie said in a statement.

  • 3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock
    InvestorPlace6 hours ago

    3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock

    During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.

  • AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
    Zacks8 hours ago

    AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

    AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacksyesterday

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Barrons.comyesterday

    Merck: Is Keytruda a $16B Drug?

     Is Wall Street underestimating Keytruda? Shares of Merck& Co. ( MRK) popped today after Citigroup’s Andrew Baum upgraded the drug maker to Buy from Neutral, and hiked his price target from $65 a share to $72 a share, citing heightened expectations for the blockbuster cancer drug. It’s been a volatile 2017 for Merck.

  • TheStreet.comyesterday

    Merck Stock Edges Higher as Citi Forecasts Strong Sales

    Citi analysts say Merck's Keytruda immunotherapy cancer drug will carry the company.

  • Benzingayesterday

    Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

    Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK ). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from ...

  • CNBCyesterday

    Merck shares jump after Citi upgrade on stronger cancer drug sales

    Keytruda is an immunotherapy drug used in cancer treatments. Citi increased its peak Keytruda sales forecast on the drug to $16 billion from $9 billion.

  • Market Realist2 days ago

    Behind Merck’s Performance in 3Q17

    MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.

  • MarketWatch3 days ago

    Lost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening

    After months of headlines about astronomical drug prices, a funny thing’s happening — drug costs are plummeting.

  • Forbes3 days ago

    The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad

    The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.

  • Better Buy: AbbVie Inc. vs. Merck
    Motley Fool5 days ago

    Better Buy: AbbVie Inc. vs. Merck

    The deck is stacked in favor of one of these big pharma stocks. But which one?

  • Capital Cube6 days ago

    Merck & Co., Inc. – Value Analysis (NYSE:MRK) : October 13, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck & Co., Inc. a score of 47. Our analysis is based on comparing Merck & Co., Inc. with the following peers – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Merck & Co Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $11.76 billion.

  • Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
    InvestorPlace6 days ago

    Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

    Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.

  • Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib
    Zacks7 days ago

    Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib

    Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.

  • Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : October 12, 2017
    Capital Cube7 days ago

    Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : October 12, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck & Co., Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • The Wall Street Journal8 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • Reuters8 days ago

    Merck says will not seek approval of cholesterol treatment

    Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings. In August, a large study on anacetrapib found that the treatment cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat tissue, leaving its commercial future uncertain. The treatment is part of a class known as CETP inhibitors designed to raise HDL, the so-called good cholesterol.

  • Company News For Oct 11, 2017
    Zacks8 days ago

    Company News For Oct 11, 2017

    Companies in the news are: CUDA,MRK,ANAB,HDSN

  • Financial Times9 days ago

    [$$] Decoding cancer: hopes rise for a new age of precision medicine

    Ever since scientists began decoding the human genome in 1990, doctors have predicted an age of "precision medicine" where patients are matched with drugs that target the specific genetic drivers ...